A double-digit increase in radiopharmaceutical sales failed to lift Covidien's pharmaceuticals unit to an overall sales gain in its fiscal second quarter.
For the period (end-March 31), the firm had pharmaceutical sales of $619 million, down 2% below adjusted sales of $631 million in the second quarter of 2009. On an operational basis, second-quarter 2010 pharmaceutical sales were down 5%.
The strong sales increase in radiopharmaceuticals was aided by a supply situation that improved from the year before and by higher thallium sales, Dublin, Ireland-based Covidien said. In other developments, sales of contrast products dipped during the quarter.
Related Reading
Covidien warns of 'extreme' Mo-99 shortage in May, March 30, 2010
SNM warns of 'significant disruptions' in Mo-99 supply, March 22, 2010
FDA, Health Canada approve Polish moly, March 11, 2010
Covidien signs deal to produce Mo-99 at Polish reactor, February 17, 2010
Covidien to halt generator production, January 22, 2010
Copyright © 2010 AuntMinnie.com
